MEDFORD, NY--(MARKET WIRE)--Sep 20, 2007 -- Chembio Diagnostics, Inc. (OTC BB:CEMI.OB - News) has been awarded a Small Business Innovative Research Phase I grant in the amount of ($286,000) from the National Institutes of Health (NIH) for the research and development of a rapid seriodiagnostic test for leptospirosis, which is recognized as an emerging infectious disease in the United States. Development of the test will be in collaboration with Weill Medical College of Cornell University in New York and the Oswaldo Cruz Foundation in Brazil, the largest research institution in Latin America.
